Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of a recombinant Staphylococcus aureus vaccine for prevention of postoperative S. aureus infection in orthopedic surgery patients
CTR20221329Phase 3Completed
- Sponsor
- Yuanlun Biotechnology
- Start
- Aug 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant staphylococcus aureus vaccine in Staphylococcus aureus infection, sponsored by Yuanlun Biotechnology. Started Aug 2022; status: completed.
02
Drugs
recombinant staphylococcus aureus vaccine
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on CTR20221329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221329.